Physician profile
Anujit Singh
NPI 1881870905
$9,632.15
in general payments reported to CMS, 2019-2025
40 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $926 · 2021: $1,595 · 2022: $795 · 2023: $1,041 · 2024: $1,588 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,129 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.88 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,877.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,037.32 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $884.39 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $872.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $647.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $624.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.09 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $456.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $309.97 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $259.24 | 2021 | |
| Exact Sciences Corporation | $250.21 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $182.11 | 2023-2024 | Accrufer |
| Janssen Pharmaceuticals, INC | $154.63 | 2019 | |
| Dexcom, INC. | $143.50 | 2021-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $141.34 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anujit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.